Hormone therapy could accentuate certain pre-existing heart disease risk factors and a heart health evaluation should become the norm when considering estrogen replacement, new research suggests. The research also showed that in women without existing atherosclerosis, hormone therapy use included some positive effects on lipids but also some negative effects related to heart health, said
Full Post: Hormone therapy could be dangerous for women pre-existing heart disease risk factors
Canadian scientists have discovered a new risk factor for cardiovascular disease and the significance of their discovery was so conclusive that the clinical trial was stopped before its scheduled completion date.
The international team of scientists have discovered that having high levels of a particular protein - high-sensitivity C-reactive protein (hs-CRP) - puts patients at increased risk of developing cardiovascular disease.
The team say this risk decreases by up to 44% if the patients are treated with statin medications.
The team included scientists from the McGill University Health Centre (MUHC) and McGill University who were taking part in the international JUPITER Project and they say the risk of cardiovascular disease due to increased hs-CRP levels has been greatly underestimated until now.
According to Dr. Jacques Genest, of the Research Institute of the MUHC, their results show that this is an extremely important indicator that doctors must in future consider.
Dr. Genest says hopefully the study will prompt a review of current clinical practices, especially in terms of screening and prevention in adults but he says more research is needed to establish specific standards.
The JUPITER study involved 17,802 patients from 27 different countries, all with normal levels of cholesterol (LDL-c) and high levels of hs-CRP, who according to current standards, were not considered “at risk” for cardiovascular events, and were therefore not receiving any treatment.
During the study the participants received a daily dose of the statin drug rosuvastin with striking results - a 44% decrease in the risk of cardiovascular disease and a 21% decrease in mortality.
The international study could revolutionize treatment options and Dr. Genest says the results surpassed predictions and were such that the study was stopped before its scheduled completion, because the benefit of the treatment was so great and needed to be presented to the medical community as soon as possible.
Statins have a cholesterol-lowering effect and are currently used to prevent cardiovascular disease in patients who are at-risk due to high LDL-c levels - however cardiovascular disease is also caused by vascular inflammation, which is marked by levels of hs-CRP and this study shows that statins act on both cholesterol and inflammation, an effect that has long been suspected but not proven.
The research was funded by drug company AstraZeneca.
Dr. Genest is Director of Cardiology at the MUHC and Director of the Cardiovascular Genetics Laboratory at the Research Institute of the MUHC and also holds the Novartis Chair in Medicine at the Faculty of Medicine of McGill University.
--------------------------------------------------------------------------------------------
Related Posts:
Many patients with cardiovascular disease are not given adequate drug therapy. This is the result of an international study. In the current edition of Deutsches ?zteblatt International ( Dtsch Arztebl Int 2008; 105[45]: 769-75), Uwe Zeimer et al. present the German results of this prospective, one-year survey. 512 doctors in Germany took part in the
Full Post: Heart patients are often not treated in accordance with guidelines
Scientists at the MUHC and McGill University have identified a gene essential for the uptake of vitamin B12 in human cells. The discovery of this gene finally completes a 24 year-old hunt for the cause of an incredibly rare genetic disorder called, cblF combined homocystinuria and methylmalonic aciduria (cblF-Hcy-MMA), first documented in a Quebec infant
Full Post: Scientists explain genetic disease first discovered in Quebec 24 years ago
Researchers at McGill University, the Research Institute of the McGill University Health Centre (RI MUHC) and the McGill University and Génome Québec Innovation Centre, along with colleagues at other Canadian and Belgian institutions, have discovered DNA variations in a gene that increases susceptibility to developing Crohn’s disease. Their study was published in the January issue
Full Post: Discovery of gene that increases susceptibility to Crohn’s disease
Resverlogix Corp. has announced key scientific data was presented in an oral presentation highlighting the novel features of RVX-208 at the American Heart Association Scientific Meeting. The presentation titled “Compound RVX-208 Modulates HDL-C Levels and Function in Non-human Primates and in Early Human Trials” was presented by Dr. Jacques Genest. Dr. Jacques Genest, MD, Director
Full Post: Resverlogix Corp shows RVX-208 demonstrates increase in functional HDL particles
Researchers estimate more than 11 million older Americans may be newly eligible for statin therapy if findings from a recently published large clinical trial are adopted into clinical practice guidelines, according to a new analysis of the trial data. The analysis is published online in Circulation: Cardiovascular Quality and Outcomes . Using data from the
Full Post: Numerical analysis estimates numbers of older US adults who may benefit from statin therapy --------------------------------------------------------------------------------------------
